Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Sponsor: Adicet Therapeutics
Summary
ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up
Official title: A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Treatment-refractory Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2025-10-10
Completion Date
2028-03-30
Last Updated
2025-12-08
Healthy Volunteers
No
Conditions
Interventions
ADI-001
Anti-CD20 CAR-T
Fludarabine
Chemotherapy for Lymphodepletion
Cyclophosphamide
Chemotherapy for Lymphodepletion
Locations (1)
Adicet Clinical Trials
Shanghai, Shanghai Municipality, China